<DOC>
	<DOCNO>NCT00702494</DOCNO>
	<brief_summary>TB-403 monoclonal antibody direct Placental Growth Factor ( PlGF ) . The antibody bind PlGF inhibit bind 's receptor , VEGF-1 . By prevent binding , growth tumor vessel inhibit tumor growth prevent . In study investigate tolerability safety TB-403 patient solid tumor receive multiple intravenous dos TB-403 .</brief_summary>
	<brief_title>Phase I Study Monoclonal Antibody TB-403 Directed Against PlGF Patients With Solid Tumours</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Confirmed malignity Measurable disease Performance status 1 less ( ECOG ) Acute illness infection Concurrent second malignancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2009</verification_date>
	<keyword>placental growth factor</keyword>
	<keyword>monoclonal antibody</keyword>
	<keyword>Phase I</keyword>
	<keyword>solid tumor</keyword>
	<keyword>Patients solid tumor</keyword>
</DOC>